The effect of LRRK2 loss-of-function variants in humans
Whiffin N., Armean IM., Kleinman A., Marshall JL., Minikel EV., Goodrich JK., Quaife NM., Cole JB., Wang Q., Karczewski KJ., Cummings BB., Francioli L., Laricchia K., Guan A., Alipanahi B., Morrison P., Baptista MAS., Merchant KM., Armean IM., Banks E., Bergelson L., Cibulskis K., Collins RL., Connolly KM., Covarrubias M., Cummings B., Daly MJ., Donnelly S., Farjoun Y., Ferriera S., Gabriel S., Gauthier LD., Gentry J., Gupta N., Jeandet T., Kaplan D., Laricchia KM., Llanwarne C., Munshi R., Neale BM., Novod S., O’Donnell-Luria AH., Petrillo N., Poterba T., Roazen D., Ruano-Rubio V., Saltzman A., Samocha KE., Schleicher M., Seed C., Solomonson M., Soto J., Tiao G., Tibbetts K., Tolonen C., Vittal C., Wade G., Wang A., Watts NA., Weisburd B., Aguilar-Salinas CA., Ahmad T., Albert CM., Ardissino D., Atzmon G., Barnard J., Beaugerie L., Benjamin EJ., Boehnke M., Bonnycastle LL., Bottinger EP., Bowden DW., Bown MJ., Chambers JC., Chan JC., Chasman D., Cho J., Chung MK., Cohen B., Correa A., Dabelea D., Darbar D., Duggirala R., Dupuis J., Ellinor PT., Elosua R., Erdmann J., Färkkilä M., Florez J., Franke A., Getz G., Glaser B., Glatt SJ., Goldstein D., Gonzalez C., Groop L., Haiman C., Hanis C., Harms M., Hiltunen M., Holi MM., Hultman CM., Kallela M., Kaprio J., Kathiresan S., Kim B-J., Kim YJ., Kirov G., Kooner J., Koskinen S., Krumholz HM., Kugathasan S., Kwak SH., Laakso M., Lehtimäki T., Loos RJF., Lubitz SA., Ma RCW., MacArthur DG., Marrugat J., Mattila KM., McCarroll S., McCarthy MI., McGovern D., McPherson R., Meigs JB., Melander O., Metspalu A., Nilsson PM., O’Donovan MC., Ongur D., Orozco L., Owen MJ., Palmer CNA., Palotie A., Park KS., Pato C., Pulver AE., Rahman N., Remes AM., Riou JD., Ripatti S., Roden DM., Saleheen D., Salomaa V., Samani NJ., Scharf J., Schunkert H., Shoemaker MB., Sklar P., Soininen H., Sokol H., Spector T., Sullivan PF., Suvisaari J., Tai ES., Teo YY., Tiinamaija T., Tsuang M., Turner D., Tusie-Luna T., Vartiainen E., Vawter MP., Ware JS., Watkins H., Weersma RK., Wessman M., Wilson JG., Xavier RJ., Ware JS., Havulinna AS., Iliadou B., Lee J-J., Nadkarni GN., Whiteman C., Agee M., Auton A., Bell RK., Bryc K., Elson SL., Fontanillas P., Furlotte NA., Hicks B., Hinds DA., Huber KE., Jewett EM., Jiang Y., Lin K-H., Litterman NK., McIntyre MH., McManus KF., Mountain JL., Noblin ES., Northover CAM., Pitts SJ., Poznik GD., Sathirapongsasuti JF., Shelton JF., Shringarpure S., Tian C., Tung JY., Vacic V., Wang X., Wilson CH., Daly M., Esko T., Hultman C., Loos RJF., Milani L., Palotie A., Pato C., Pato M., Saleheen D., Sullivan PF., Alföldi J., Cannon P., MacArthur DG.
Abstract Human genetic variants predicted to cause loss-of-function of protein-coding genes (pLoF variants) provide natural in vivo models of human gene inactivation and can be valuable indicators of gene function and the potential toxicity of therapeutic inhibitors targeting these genes 1,2 . Gain-of-kinase-function variants in LRRK2 are known to significantly increase the risk of Parkinson’s disease 3,4 , suggesting that inhibition of LRRK2 kinase activity is a promising therapeutic strategy. While preclinical studies in model organisms have raised some on-target toxicity concerns 5–8 , the biological consequences of LRRK2 inhibition have not been well characterized in humans. Here, we systematically analyze pLoF variants in LRRK2 observed across 141,456 individuals sequenced in the Genome Aggregation Database (gnomAD) 9 , 49,960 exome-sequenced individuals from the UK Biobank and over 4 million participants in the 23andMe genotyped dataset. After stringent variant curation, we identify 1,455 individuals with high-confidence pLoF variants in LRRK2 . Experimental validation of three variants, combined with previous work 10 , confirmed reduced protein levels in 82.5% of our cohort. We show that heterozygous pLoF variants in LRRK2 reduce LRRK2 protein levels but that these are not strongly associated with any specific phenotype or disease state. Our results demonstrate the value of large-scale genomic databases and phenotyping of human loss-of-function carriers for target validation in drug discovery.